Form 4: Castle Biosciences Director Receives RSU Grant

Director Ellen Goldberg was granted 11,766 restricted stock units in Castle Biosciences, Inc. as part of an equity compensation arrangement.

Summary

• Director Ellen Goldberg received a grant of 11,766 Restricted Stock Units (RSUs) on May 28, 2026.
• Each RSU represents a contingent right to receive one share of Castle Biosciences common stock.
• The grant is fully vested on the earlier of the one-year anniversary of the grant date (May 28, 2027) or the day before the next annual meeting of stockholders.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or financial health.

Positives

• Equity-based compensation aligns the interests of the director with those of the shareholders.

Negatives

• The grant results in potential future dilution for existing shareholders upon the vesting and conversion of the RSUs.

Risks

• Market volatility could impact the future value of the equity granted to the director.

Future Outlook

The RSUs are scheduled to vest in full on May 28, 2027, or the day prior to the next annual meeting of stockholders, whichever occurs first.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice in the biotechnology sector to ensure long-term alignment with shareholder interests.

Comparison to Industry Standards

• The use of RSUs for director compensation is consistent with standard practices for mid-cap biotechnology companies.
• Vesting schedules of one year or until the next annual meeting are typical for board-level equity awards.

Stakeholder Impact

• Minor dilution impact on existing shareholders upon future vesting.

Next Steps

• Vesting of the 11,766 RSUs on May 28, 2027, or the day before the next annual meeting.

Key Dates

Keywords

Castle Biosciences, CSTL, Form 4, Insider Trading, Restricted Stock Units, Equity Compensation